QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 i-mab-to-present-updated-phase-1-givastomig-data-in-gastroesophageal-cancer-at-major-oncology-conference

I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncolog...

 leerink-partners-initiates-coverage-on-i-mab-with-outperform-rating-announces-price-target-of-9

Leerink Partners analyst Daina Graybosch initiates coverage on I-MAB (NASDAQ:IMAB) with a Outperform rating and announces Pr...

 btig-reiterates-buy-on-i-mab-maintains-7-price-target

BTIG analyst Justin Zelin reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $7 price target.

 btig-initiates-coverage-on-i-mab-with-buy-rating-announces-price-target-of-7

BTIG analyst Justin Zelin initiates coverage on I-MAB (NASDAQ:IMAB) with a Buy rating and announces Price Target of $7.

 needham-reiterates-buy-on-i-mab-maintains-6-price-target

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $6 price target.

 i-mab-accelerates-givastomig-development-with-global-phase-2-trial-in-metastatic-gastric-cancer-expands-pipeline-and-appoints-wei-fu-as-executive-chairman

Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in ...

 hc-wainwright--co-reiterates-buy-on-i-mab-maintains-7-price-target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $7 price target.

 needham-maintains-buy-on-i-mab-raises-price-target-to-6

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and raises the price target from $5 to $6.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION